Range Low Price High Price Comment
30 days $2.35 $3.48 Tuesday, 30th Apr 2024 XTLB stock ended at $2.59. This is 7.02% more than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 4.00% from a day low at $2.50 to a day high of $2.60.
90 days $0.768 $4.99
52 weeks $0.750 $4.99

Historical XTL Biopharmaceuticals Ltd. prices

Date Open High Low Close Volume
Feb 01, 2016 $6.55 $6.75 $6.25 $6.30 1 080
Jan 29, 2016 $6.80 $6.80 $6.60 $6.60 280
Jan 28, 2016 $6.75 $6.75 $6.75 $6.75 0
Jan 27, 2016 $6.75 $6.75 $6.75 $6.75 0
Jan 26, 2016 $5.35 $7.00 $4.10 $6.75 7 060
Jan 25, 2016 $7.50 $7.95 $6.80 $6.95 8 500
Jan 22, 2016 $6.25 $7.50 $6.25 $6.80 14 260
Jan 21, 2016 $6.20 $7.55 $5.70 $6.95 4 720
Jan 20, 2016 $6.80 $6.80 $6.80 $6.80 0
Jan 19, 2016 $6.80 $6.80 $6.80 $6.80 20
Jan 15, 2016 $6.30 $6.30 $6.30 $6.30 60
Jan 14, 2016 $6.50 $6.50 $6.50 $6.50 0
Jan 13, 2016 $6.55 $6.55 $6.50 $6.50 540
Jan 12, 2016 $6.75 $6.75 $6.75 $6.75 60
Jan 11, 2016 $7.50 $7.50 $6.55 $6.55 2 040
Jan 08, 2016 $7.15 $7.15 $7.15 $7.15 0
Jan 07, 2016 $7.40 $7.45 $7.00 $7.15 720
Jan 06, 2016 $7.10 $7.40 $7.10 $7.40 560
Jan 05, 2016 $7.50 $7.50 $7.50 $7.50 120
Click to get the best stock tips daily for free!

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCD... XTLB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT